Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage.
The post Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor appeared first on MedCity News.
